Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Testing gene expression changes in VCaP cells following PRMT5 knockdown

ABSTRACT: VCaP cells expressing either NTC shRNA or PRMT5 shRNA 1 or shRNA 2 were treated with 100ng/ml doxycycline for 5 days This experiment is designed to see which genes and pathways are modulated by PRMT5 knockdown in VCaP cells VCaP cells were treated with 100ng/ml doxyxycline for 3 days.

ORGANISM(S): Homo sapiens

SUBMITTER: Joshua Korn

PROVIDER: E-GEOD-65965 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Testing gene expression changes in VCaP cells following PRMT5 knockdown

Project description:VCaP cells expressing either NTC shRNA or PRMT5 shRNA 1 or shRNA 2 were treated with 100ng/ml doxycycline for 5 days This experiment is designed to see which genes and pathways are modulated by PRMT5 knockdown in VCaP cells

2015-04-15 | GSE65965 | GEO

Testing gene expression changes in VCaP upon depletion of the mutated ETS transcription factor ERG

Project description:VCaP cells expressing inducible shRNAs for either ERG or a non-targeting control were treated with Doxycycline for 1, 3, 7 and 10 days prior to collection This experiment is designed to see which genes and pathways are modulated by ERG knockdown VCaP cells stably expressing a Doxycycline (dox)-inducible control nontargeting shRNA (Pak4) or an ERG shRNA (2217) were exposed to 100ng/ml Dox for the noted days.

2014-08-27 | E-GEOD-60771 | biostudies-arrayexpress

Transcriptional responses of mantle cell lymphoma (MCL) after NIK knockdown

Project description:MCL lines were treated with or without 100ng/ml doxycycline for 7 days This experiment is designed to see if shRNA-mediated knockdown of NIK downregulates NFKB signaling in MCL lines with mutations in upstream regulators of the alternative pathway (TRAF2 & TRAF3) MCL cells carrying inducible non-targeting control (NTC) shRNA, NIKshRNA#1 (NIKsh#1), or NIKshRNA#2 (NIKsh#2) were seeded in 6well dishes and treated for 7 days with or without 100ng/ml doxycycline.

2013-12-01 | E-GEOD-52435 | biostudies-arrayexpress

AR and ERG ChIP-seq in presence or absence of PRMT5

Project description:Replicates of ChIP seq data using AR and ERG antibodies from VCaP cell lines harboring inducible shRNA constructs for PRMT5 (3 independent, sh1, sh2, sh3) and 1 non targeting control (NTC), all sample stimulated with ligand, either DHT or R1881

2016-05-20 | GSE79128 | GEO

Identification of targets regulated by MLL1 in response to HSP90 inhibitors

Project description:MLL1 WT or KO MEF with and without HSP90 inhibitor treatment MEF cells were seeded in 6-well plates for 3d with 100ng/ml doxycycline prior to treatment with 0.1% DMSO or 100nM AUY922 for 3h

2014-04-15 | E-GEOD-56492 | biostudies-arrayexpress

Identification of targets regulated by HSF1 in response to HSP90 inhibitors

Project description:A375 cells with inducible knockdown HSF1 with and without HSP90 inhibitor treatment A375 cells were seeded in 6-well plates for 3d with 100ng/ml doxycycline prior to treatment with 0.1% DMSO or 100nM HSP990 for 3h

2013-03-06 | E-GEOD-44867 | biostudies-arrayexpress

Testing rescue of AR signaling by ectopic expression of mutant AR allele in the presence of MDV-3100

Project description:Genetically engineered LNCaPs overexpressing various AR alleles were treated with 0.1% DMSO or 10uM MDV3100 for 24h prior to collection This experiment is designed to see if expressing the F876L/T877A mutant AR can rescue AR signaling in the presence of MDV3100 Engineered lines were seeded in 6-well plates for 3d with 100ng/ml doxycycline prior to treatment with 0.1% DMSO or 10uM MDV3100 for 24h

2013-09-30 | E-GEOD-44924 | biostudies-arrayexpress

Identification of NEDD9 regulated genes in VCaP prostate cancer cells

Project description:NEDD9 gene (Neural precursor Expressed, Developmentally Down-regulated 9) encodes a member of the Cas family of signaling transduction molecules, which is a non-catalytic focal adhesion protein phosphorylated by FAK and Src and functions as a signaling hub to regulate downstream signaling, such as the AKT pathway. In cancers, NEDD9 regulates cell migration, epithelial-mesenchymal transition (EMT), invasion, and metastasis. Gene amplification of NEDD9 is commonly found in the advanced metastatic castration-resistant PCa (~3%) and neuroendocrine PCa (~15%), suggesting NEDD9 may play an important role in PCa progression. In order to characterize the global functions of NEDD9 in PCa cells, we performed RNA-seq analyses in VCaP cells (containing NEDD9 gene amplification) stably infected with shRNA against NEDD9 or non-targeting control (NTC).

2021-01-11 | GSE164531 | GEO

Genome-wide analysis of genes regulated by p44/wdr77 and PRMT5 in lung and prostate cancer cells

Project description:Analysis of gene expression in lung and prostate cancer cells expressing non-target (NT), p44/wdr77. or PRMT5 shRNA. Results provide important information on how p44/wdr77 and PRMT5 control cellular proliferation. Total RNA obtained from cells expressing NT, p44/wdr77, or PRMT5 shRNA.

2014-04-14 | E-GEOD-56757 | biostudies-arrayexpress

PRMT5 inhibition increases PD-L1 expression and immunoresistance in lung cancer

Project description:Purpose: We sequenced mRNA from 3 biological replicates each of NCI-H460 lung adenocarcinoma cell lines expressing shRNA against GFP (control) or PRMT5.We then determined differential gene expression to identify the relationship between PRMT5 expression and tumorigenesis. Methods: PRMT5 shRNA and control shRNA NCI-H460 cells were generated by lentivirus targeting PRMT5 or GFP(control), in triplicate,using illumina Novaseq™ 6000. Results:PRMT5 specific knockdown cells were enriched in the negative regulation of T cells and type I IFN response,we found that negative regulation of T cell molecules like Arg2, CD274 and IDO1 were increased in the PRMT5 shRNA group compared with the control group.

2022-02-08 | GSE178521 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data